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Abstract
Background Hypoglycaemia is a common side effect of 
insulin therapy and presents a barrier to diabetes man-
agement, however, limited data exist on the real-world 
frequency of events. We investigated the self-reported 
rates of non-severe and severe hypoglycaemic events 
in Austria. We also explored hypoglycaemia aware-
ness, patient–physician communication and the health-
related and economic impact of events.
Methods People with Type-1 or insulin-treated 
Type-2 diabetes > 15 years of age completed up to 4 ques-
tionnaires (weekly intervals). Non-severe hypoglycaemic 
events were defined by requiring no assistance while 
severe hypoglycaemic events need help from a third 
party.
Results Overall, 553 respondents (40 % Type-1, 60 % 
Type-2) enrolled, providing a total of 1,773 patient-
weeks. The mean annual non-severe event frequencies 
were 85 for Type-1 and 15–28 for Type-2 (depending on 
insulin regimen). In respondents who experienced ≥ 1 
non-severe event in the study period, annual rates were 
18 % higher in Type-1 and 77 % higher in Type-2. The pro-
portion of respondents reporting ‘awareness’ of hypogly-
caemic symptoms was 48 % for Type-1 and 43–61 % for 
Type-2 respondents. The proportion of respondents who 
rarely/never inform their physician of hypoglycaemic 
events was 67 % (Type-1) and 43–53 % (Type-2). The most 
commonly reported health-related impacts were tired-
ness/fatigue (58 % of events) and reduced alertness (41 % 
of events).
Conclusion Non-severe hypoglycaemic events are 
common in Type-1 and insulin-treated Type-2 diabetes 
patients in Austria. There may be subgroups of patients 
who are predisposed to higher rates of non-severe events. 
Even non-severe events have a negative impact on physi-
cal and emotional well-being.
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Häufigkeit und Auswirkung von Hypoglykämien 
bei insulinbehandelten Diabetes-Patienten in 
Österreich
Zusammenfassung
Grundlagen Hypoglykämien sind ein häufiger Neben-
effekt der Insulintherapie und stellen eine Limitation im 
Diabetesmanagement dar, dennoch gibt es nur wenig 
Daten zu solchen Ereignissen im Alltag. Wir haben 
deshalb die Häufigkeit von selbst beobachteten nicht-
schweren und schweren Hypoglykämien in Österreich 
untersucht. Ebenfalls untersucht wurden Hyoglykä-
miewahrnehmung, Patient-Arzt Kommunikation und 
gesundheitliche sowie ökonomische Auswirkungen von 
Hypoglykämien.
Methodik Personen mit Typ 1 oder insulin-behan-
deltem Typ 2 Diabetes ( > 15 Lj.) füllten in wöchentlichen 
Abständen bis zu 4 Fragebögen aus. Nicht-schwere Hypo-
glykämien (NSHE) wurden als solche ohne, schwere als 
solche mit von außen benötigter Hilfe definiert.
Ergebnisse Der Fragebogenrücklauf belief sich auf 
533 Personen (40 % Typ 1, 60 % Typ 2), insgesamt 1.773 
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Patientenwochen entsprechend. Die durchschnittliche 
jährliche NSHE-Häufigkeit betrug 85 bei Typ 1 und 15–28 
(abhängig von der Art des Insulinregimes) bei Typ 2. Bei 
Patienten, die ≥ 1 NSHE während der Studiendauer hat-
ten, war die jährliche Hypoglykämierate bei Typ 1  um 
18 %, bei Typ 2 um 77 % erhöht. Der Anteil der Patienten 
mit „Wahrnehmung“ hypoglykämischer Symptome lag 
bei 48 % für Typ 1 und 43–61 % für Typ 2. Der Anteil der 
Patienten, die selten/nie ihren Arzt über Hypoglykämien 
informieren, war 67 % bei Typ 1 und 43–53 % bei Typ 2.
Die am häufigsten berichteten gesundheitsbezoge-
nen Auswirkungen waren Müdigkeit/Erschöpfung (58 % 
der NSHE) und eingeschränkte Aufmerksamkeit (41 % 
der NSHE).
Schlussfolgerung NSHE sind bei Typ 1 und insulin-
behandelten Typ 2 Diabetespatienten in Österreich häu-
fig. Subgruppen von Patienten mit einer Prädisposition 
für höhere Raten von NSHE könnten definiert werden. 
Selbst NSHE haben einen negativen Effekt auf das kör-
perliche und emotionale Wohlbefinden.
Schlüsselwörter Diabetes mellitus · Hypoglykämie · In-
sulin · Lebensqualität
Introduction
According to the International Diabetes Federation 
(IDF) more than 56 million adults in Europe have been 
diagnosed with diabetes mellitus (2013 estimate), corre-
sponding to a prevalence of 6.8 % [1]. The prevalence in 
Austria is slightly higher, at 8–9 % [2].
A fundamental goal in the management of patients 
with diabetes is the maintenance of normoglycaemia, 
often through the use of insulin [3]. However, intensi-
fication of insulin therapy can increase the incidence 
of hypoglycaemia; the most common and unpredict-
able side effect of insulin treatment [4]. Hypoglycaemia 
can be defined as either non-severe or severe accord-
ing to whether a patient can manage the event alone or 
requires third party assistance, respectively [5, 6]. Non-
severe hypoglycaemic events (NSHEs), which account 
for 88–98 % of all events [7, 8], are associated with a nega-
tive impact on health-related quality of life, healthcare 
resource use and work productivity [7, 9, 10].
Hypoglycaemia presents a significant barrier to opti-
mal diabetes management as fear of hypoglycaemic 
events may cause exaggerated avoidance behaviour and 
consequently sub-optimal insulin therapy and glycae-
mic control [11, 12]. Therefore, diabetes education has 
a critical role in diabetes management, and all diabetes 
patients in Austria are offered structured diabetes educa-
tion, which aims to minimise the risk of diabetes-related 
complications and premature mortality. For Type 2 
patients, a Disease Management Programme (DMP) for 
regular diabetes care by GPs was introduced in 2007 [13]. 
However, only 15–20 % of Type 2 patients have enrolled 
in the programme, demonstrating an ongoing need for 
improved patient engagement in the management of 
their diabetes. Alongside patients, all physicians who 
care for people with diabetes are expected to attend the 
programme [13].
In Europe, data on the frequency of hypoglycaemia 
outside of clinical trial settings are limited and varied. 
The majority of literature focuses on Type 1 diabetes and 
the frequency of severe hypoglycaemic events (SHE). 
Four European studies have reported real-world esti-
mates of NSHE rates [4, 8, 10, 14], however there are no 
data specific to the Austrian setting. The results of previ-
ous studies vary according to their definition of hypogly-
caemic events, methods of data collection, and country 
coverage. Therefore there is a clear need to gain a better 
understanding of the patient perspective on the bur-
den of hypoglycaemia, and their communication with 
healthcare professionals (HCPs) on the subject.
This paper reports the frequency of self-reported 
NSHEs and SHEs in people with Type 1 and insulin-
treated Type 2 diabetes mellitus (T1DM and T2DM) in 
Austria. Additionally, levels of impaired hypoglycaemia 
awareness, patient–physician communication of hypo-
glycaemic events and the health-related effects and eco-
nomic impact of NSHEs are reported.
Patients, materials and methods
A full description of the methodology for this study has 
been previously described by Östenson et al., who inves-
tigated self-reported NSHE rates across seven Northern 
and Central European countries (Austria, Denmark, 
Finland, Norway, Sweden, Switzerland and the Nether-
lands) [15, 16].
The questionnaire-based survey was conducted in 
Austria between February and May 2012 People over the 
age of 15 with a T1DM or T2DM diagnosis receiving insu-
lin were recruited using existing large online panels that 
provided a representative sample of the general diabetes 
population based on age, gender and other demographic 
characteristics. Respondents with T2DM were divided 
into three subgroups based on their insulin regimen: 
long acting-insulin only (basal only therapy; T2BOT), 
short and long acting insulin (basal-bolus; T2BB) or 
other insulin regimens (e.g. premix; T2O).
A small incentive was offered for completion of the 
questionnaire (approximately € 5–10 in total), in line with 
current market research guidelines and to ensure there 
was no undue incentive to participate. Questionnaires 
were completed anonymously in accordance to the regu-
lations and practice of market research governing bodies 
European Society for Opinion and Marketing Research 
(ESOMAR) [17] and European Pharmaceutical Market 
Research Association (EphMRA) [18].
Participants were invited to complete four question-
naires over four consecutive weeks. The first question-
naire collected information on respondent demographics, 
awareness of hypoglycaemic symptoms, communication 
of hypoglycaemic events with HCPs, frequency of NSHEs 
in the previous seven days, and the number of SHEs in the 
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respondents were comparable regardless of the level of 
awareness (data not shown). There may also be an asso-
ciation between HbA1c levels and awareness, however, 
opposing trends are observed according to diabetes type. 
In T1DM respondents, low HbA1c corresponded with 
reduced unawareness (6.7 % in unaware versus 7.4 % in 
past year. The subsequent three questionnaires recorded 
only the frequency of NSHEs in the preceding seven days, 
and the impact of the most recent event. Data collected on 
the impact of hypoglycaemia included changes in respon-
dent well-being, work productivity and healthcare resource 
use. Weekly NSHE frequencies were calculated using data 
from all participants completing at least one questionnaire 
(wave), with annual frequency calculated using the mean 
weekly event frequency multiplied by 52. NSHE frequen-
cies are also presented for only those respondents who 
experienced a NSHE during the recall report.
The classification system for awareness of hypogly-
caemia was based on a prospectively validated study 
by Pedersen-Bjergaard et al. [19]. Any respondent who 
answered ‘sometimes’ or ‘never’ to the question ‘can 
you feel when your blood sugar is low?’ was assigned as 
being unaware of hypoglycaemia, those who answered 
‘usually’ as having impaired awareness and those who 
answered ‘always’ deemed to be aware.
Standard descriptive methods (means/percentage 
and standard deviations) were used to report results. 
Comparisons of NSHE frequencies according to respon-
dent awareness and patient–physician communication 
were performed using t-tests with an employed signifi-
cance level of p < 0.05.
Results
Overall 553 respondents completed the first wave, with 
82 %, 72 % and 67 % completing waves 2, 3 and 4, respec-
tively. This gives a total of 1,773 patient-week records in 
Austria. Patient demographics are shown in Table 1. In 
total, 40 % of respondents had T1DM and 60 % of respon-
dents had T2DM.
The mean annual self-reported frequencies of NSHE 
were 85 for T1DM, 22 for T2DM, 15 for T2BOT, 28 for 
T2BB and 19 for T2O. Analysing results only from those 
respondents who experienced a NSHE during the recall 
period, annual NSHE rates were 100 in T1DM and 39 in 
T2DM (ranging from 33 in T2O to 43 in T2BB) (Table 2). 
The proportion of NSHEs which occurred at night-time 
was 19 % for T1DM and 21 % for T2DM respondents. After 
excluding respondents who did not experience any noc-
turnal NSHEs during the study period, the proportion of 
events occurring at night-time increased to 23 % (n = 29) 
in T1DM and 39 % (n = 20) in T2DM (Table 3).
Self-reported mean annual SHE frequencies were 0.7 
for T1DM and 0.2 for T2DM (0.1 for T2BOT, 0.2 for T2BB 
and 0.2 for T2O).
The proportion of respondents who are reportedly 
‘aware’ of hypoglycaemic symptoms was 48 % in T1DM 
and 57 % in T2DM respondents. Respondents who 
reported impaired awareness comprised 44 % of T1DM 
respondents and 31 % of T2DM respondents, with 7 and 
12 % being unaware, respectively (Table  4). For T1DM 
respondents, there was a trend for increased NSHE and 
SHE rates with decreasing awareness, however this was 
not significant (data not shown). NSHE rates for T2DM 
Table 1 Respondent demographics
Type 1 Type 2
Number of respondents, N (%) 222 (40 %) 331 (60 %)
Age, mean (SD) 44.5 (14.6) 62.8 (11.9)
Gender, female, N (%) 113 (51 %) 137 (41 %)
Marital status, N (%)
Single 61 (27 %) 78 (24 %)
Married 109 (49 %) 211 (64 %)
Partner 52 (23 %) 42 (13 %)
Living arrangements, N (%)
Alone 34 (15 %) 74 (22 %)
With others 188 (85 %) 257 (78 %)
Active employment, N (%) 143 (64 %) 74 (22 %)
Education, N (%)
Primary school 67 (30 %) 159 (48 %)
High school 101 (46 %) 137 (41 %)
University 48 (22 %) 28 (8 %)
Other 6 (3 %) 7 (2 %)
BMI, mean (SD) 25.5 (4.8) 29.9 (5.7)
Diabetes duration, N (%)
Mean years (SD) 20.2 (13.5) 16.4 (10.3)
< 2 years 7 (3 %) 3 (1 %)
2–5 years 21 (10 %) 37 (12 %)
5–9 years 30 (14 %) 44 (14 %)
10–14 years 30 (14 %) 63 (20 %)
15 + years 126 (59 %) 165 (53 %)
Insulin treatment type, N (%)
Basal-only therapy 13 (6 %) 76 (23 %)
Basal-bolus therapy 135 (61 %) 162 (49 %)
Other insulin types 74 (33 %) 93 (28 %)
Duration of insulin treatment, N (%)
Average in years (SD) 18.5 (13.5) 8.3 (6.7)
< 2 years 13 (6 %) 38 (12 %)
2–5 years 27 (13 %) 91 (29 %)
5–9 years 25 (12 %) 61 (20 %)
10 + years 149 (70 %) 122 (39 %)
Mean HbA1c
mean mmol/mol (SD) 55.4 (11.5) 61.3 (18.8)
NGSP %, (SD) 7.2 (1.1) 7.8 (1.7)
Medical complicationsa, none, N (%) 152 (68 %) 125 (38 %)
BMI Body mass index, HbA1c Haemoglobin A1c (glycosylated haemoglobin), 
NGSP National Glycohaemoglobin Standardisation Programme, SD Standard 
deviation
aQuestionnaire options for medical complications included: None, Eye 
problems, Neuropathy, Cardiovascular disease, Renal disease, Amputations, 
Other (please specify)
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Respondents reported negative health-related 
impacts following their last NSHE, including feeling 
tired/fatigued (following 54 and 61 % of NSHE in T1DM 
and T2DM, respectively), less alert (39 and 42 % of NSHE 
in T1DM and T2DM) and ill/uncomfortable (19 and 22 % 
of NSHE in T1DM and T2DM). Respondents’ emotional 
wellbeing was also affected, with NSHE resulting in feel-
ing emotionally low (following 32 and 35 % of NSHE in 
T1DM and T2DM, respectively), anxious/nervous (26 
and 40 % in T1DM and T2DM) and moody (18 and 19 % 
in T1DM and T2DM) (Fig. 1). The number of hours nega-
tive feelings lasted for was greater in T2DM respondents 
(7 h in T2DM versus 4 h in T1DM). Events which occurred 
aware patients), however in T2DM higher HbA1c corre-
sponded with reduced awareness (8.4 % in unaware ver-
sus 7.6 % in aware patients).
Overall, 67 % of T1DM and 49 % of T2DM respondents 
rarely or never inform their general practitioner (GP)/
specialist about hypoglycaemic events. When respon-
dents were asked about topics discussed during GP/
specialist consultations, 18 % of T1DM and 20 % of T2DM 
respondents reported that their GP/specialist did not 
ask about hypoglycaemia during routine appointments 
(Table 5). NSHE rates were similar regardless of the level 
of patient–physician communication (data not shown).
Table 2 Self-reported, recalled rates of hypoglycaemic events (daytime and nocturnal combined)
All respondents (1773 respondent-week records from  
553 respondents)
T1DM (n = 222; 
716 pw)
T2DM
T2DM (n = 331; 
1,057 pw)
T2BOT (n = 76; 
248 pw)
T2BB (n = 162; 
532 pw)
T2O (n = 93; 
277 pw)
Annual calculated NSHE rates (52 weeks), mean 84.6 22.5 15.1 27.8 19.0
Patients who experienced ≥ 1 NSHE in study period, n (%) 177 (80 %) 174 (53 %) 28 (37 %) 99 (61 %) 47 (51 %)
Respondents who experienced ≥ 1 NSHE in the study period  
(daytime or nocturnal)
T1DM (n = 177; 
605 pw)
T2DM (n = 174; 
605 pw)
T2BOT (n = 28; 
103 pw)
T2BB (n = 99; 
343 pw)
T2O (n = 47; 
159 pw)
NSHEs/year, mean 100.1 39.3 36.3 43.1 33.0
Nocturnal NSHEs/year, mean (% of all NSHEs) 19.1 (19 %) 8.1 (21 %) 8.1 (22 %) 9.6 (22 %) 4.9 (15 %)
Base: All respondent-weeks reported; includes all respondents regardless of whether completing all four questionnaires
NSHE Non-severe hypoglycaemic event, SD Standard deviation, T1DM Type 1 diabetes mellitus, T2BB Type 2 diabetes mellitus respondents receiving basal bo-
lus therapy/short and long acting insulin, T2BOT Type 2 diabetes mellitus respondents receiving basal only therapy/long acting insulin only, T2O Type 2 diabetes 
mellitus respondents receiving other therapy (e.g. mixed insulin)
Table 3 Self-reported, recalled rates of non-severe hypoglycaemic events (nocturnal only)
All respondents  (1773 respondent-week records from  
553 respondents)
T1DM (n = 222; 
716 pw)
T2DM
T2DM (n = 331; 
1,057 pw)
T2BOT (n = 76; 
248 pw)
T2BB (n = 162; 
532 pw)
T2O (n = 93; 
277 pw)
Nocturnal NSHEs/year, mean (% of al NSHEs) 16.1 (19 %) 4.6 (21 %) 3.4 (22 %) 6.2 (22 %) 2.8 (15 %)
Patients who experienced ≥ 1 nocturnal NSHE in study period, n (%) 110 (50 %) 72 (22 %) 10 (13 %) 48 (30 %) 14 (15 %)
Respondents who experienced ≥ 1 nocturnal NSHE in the study 
period
T1DM (n = 110; 
392 pw)
T2DM (n = 72; 
48 pw)
T2BOT (n = 10; 
40 pw)
T2BB (n = 48; 
162 pw)
T2O (n = 14; 
46 pw)
NSHEs/year, mean 127.3 50.3 54.6 51.7 41.9
Nocturnal NSHE/year, mean 29.4 (23 %) 19.7 (39 %) 20.8 (38 %) 20.2 (39 %) 17.0 (41 %)
Base: All respondent-weeks reported; includes all respondents regardless of whether completing all four questionnaires
NSHE Non-severe hypoglycaemic event, SD Standard deviation, T1DM Type 1 diabetes mellitus, T2BB Type 2 diabetes mellitus respondents receiving basal bo-
lus therapy/short and long acting insulin, T2BOT Type 2 diabetes mellitus respondents receiving basal only therapy/long acting insulin only, T2O Type 2 diabetes 
mellitus respondents receiving other therapy (e.g. mixed insulin)
Table 4 Self-reported respondent awareness of hypoglycaemia
All respondents who have previously  
experienced a NSHE† (n = 396)
T1DM (n = 189) T2DM
All T2DM (n = 207) T2BOT (n = 35) T2BB (n = 115) T2O (n = 57)
Can you feel when 
your blood sugar is 
low? N (%)
Always aware 91 (48 %) 119 (57 %) 15 (43 %) 69 (60 %) 35 (61 %)
Impaired awareness 84 (44 %) 64 (31 %) 10 (29 %) 38 (33 %) 16 (28 %)
Unaware 14 (7 %) 24 (12 %) 10 (29 %) 8 (7 %) 6 (11 %)
Hypoglycaemia ‘awareness’ relates to the respondents’ self-reported ability to recognise the physical symptoms indicating the onset of a hypoglycaemic event. 
†Base: all respondents that have previously experienced a NSHE at any point (not just in study recall period)
NSHE Non-severe hypoglycaemic event, T1DM Type 1 diabetes mellitus, T2BB Type 2 diabetes mellitus respondents receiving basal bolus therapy/short and 
long acting insulin, T2BOT Type 2 diabetes mellitus respondents receiving basal only therapy/long acting insulin only, T2DM Type 2 diabetes mellitus, T2O Type 
2 diabetes mellitus respondents receiving other therapy (e.g. mixed insulin)
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use increased by a mean of 4.1 (13 %) in T1DM and 3.7 
(17 %) in T2DM respondents. In T1DM and T2DM respon-
dents combined, 6 % of NSHE led respondents to contact 
a HCP (Table  6). A greater proportion of respondents 
with T2DM contacted a HCP, regardless of the time of day 
that the event occurred (daytime NSHE: 10 %, nocturnal 
NSHE 9 %). In employed T1DM respondents (n = 143), 8 % 
of NSHE led to lost work time with approximately 3.0  h 
work time lost per event. In employed T2DM respondents 
(n = 74), 14 % of NSHE led to lost work time, with approxi-
mately 4.3 h work time lost per event (Table 6).
Discussion
This study evaluates the real world frequency of NSHEs 
and SHEs in people with T1DM and insulin-treated 
at night-time had a longer lasting impact than events 
during the day: 7 versus 4 h in T1DM and 8 versus 6 h in 
T2DM. NSHEs also impacted upon respondents’ daily 
routine. The three most common impacts were reduced 
energy levels, daytime sleeping and difficulty concen-
trating. These overall findings were reflected in the spe-
cific results for respondents with T1DM or T2DM. T1DM 
respondents reported having less energy than usual fol-
lowing 34 % (daytime) and 50 % (nocturnal) of NSHE, 
with 25 % (daytime) and 23 % (nocturnal) NSHE resulting 
in daytime sleeping. T2DM respondents reported similar 
trends with 56 % of daytime and 32 % of nocturnal NSHE 
resulting in reduced energy levels and 56 % (daytime) and 
29 % (nocturnal) of NSHE leading to daytime sleeping.
NSHEs reported during the study period resulted in 
increased use of healthcare resources (Table 6) [16]. Over 
the seven days following a NSHE, blood glucose test-strip 
Table 5 Patient–physician communication of hypoglycaemia
All respondents who have previously experienced a NSHEa 
(n = 396)
T1DM (n = 189) T2DM
All T2DM (n = 207) T2BOT (n = 35) T2BB (n = 115) T2O (n = 57)
Proportion of respondents who rarely/never inform their GP/
specialist about NSHEs, N (%)
126 (67 %) 101 (49 %) 15 (43 %) 56 (49 %) 30 (53 %)
Based on all respondents completing wave 1 (n = 553)b T1DM (n = 222) All T2DM (n = 331) T2BOT (n = 76) T2BB (n = 162) T2O (n = 93)
GP/specialist did not ask about hypoglycaemia during routine 
appointments
18 % 20 % 14 % 25 % 16 %
NSHE Non-severe hypoglycaemic event, SD Standard deviation, T1DM Type 1 diabetes mellitus, T2BB Type 2 diabetes mellitus respondents receiving basal 
bolus therapy/short and long acting insulin, T2BOT Type 2 diabetes mellitus respondents receiving basal only therapy/long acting insulin only, T2DM Type 2 
diabetes mellitus, T2O Type 2 diabetes mellitus respondents receiving other therapy (e.g. mixed insulin)
aBase: all respondents that have previously experienced a NSHE at any point (not just in study recall period)
bBase: All respondents completing wave 1 (n = 396)
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Fig. 1 Negative health-related impacts of NSHEs. 
From left to right: most common response to least common response, based on combined results from Type 1 diabetes mellitus 
and Type 2 diabetes mellitus. NSHE Nonsevere hypoglycaemic event, T1DM Type 1 diabetes mellitus, T2BB Type 2 diabetes 
mellitus respondents receiving basal bolus therapy/short and long acting insulin, T2BOT Type 2 diabetes mellitus respondents 
receiving basal only therapy/long acting insulin only, T2DM Type 2 diabetes mellitus, T2O Type 2 diabetes mellitus respondents 
receiving other therapy (e.g. mixed insulin)
original article
Self-reported frequency and impact of hypoglycaemic events in insulin-treated diabetic patients in Austria  411 3
T2DM increases with increasing diabetes duration [8], 
and Henderson et al. [22] reported that NSHE frequency 
among people with T2DM only reaches the same level 
as in people with T1DM after 10 years of insulin use in 
T2DM [22]. In the present study, only 39 % of respondents 
with T2DM had received insulin for over 10 years (com-
pared to 70 % of respondents with T1DM), which may 
help to explain the lower frequency of NSHEs. In T2DM 
the frequency of NSHE also varies according to treatment 
regimen, although this is expected due to the different 
types of insulin coverage [23].
Although we report a mean annual NSHE rate of 85 
in T1DM and 22 in T2DM patients in Austria, sub-anal-
yses suggest that some patients are more susceptible to 
hypoglycaemia. Over a third (37 %) of all respondents did 
not experience any NSHEs during the four week study 
period; a sub-analysis excluding these respondents 
increases the mean annual NSHE rate by 18 % in respon-
dents with T1DM, and by 77 % in respondents with 
T2DM (ranging from a 54 % increase in T2BOT to 140 % 
in T2BOT respondents). Looking specifically at nocturnal 
events, although the mean annual rate was 16 in T1DM 
and 5 in T2DM respondents, 50 % of respondents with 
T1DM and 78 % of T2DM respondents did not experience 
any nocturnal NSHEs during the study. A sub-analysis 
of the respondents who reported at least one nocturnal 
event resulted in nearly double the nocturnal NSHE rate 
in T1DM and increased it 4-fold in T2DM respondents. 
These results suggest an increased risk of hypoglycaemia 
in patients with a history of events, a finding which has 
been reported previously [24–30]. As some patients may 
not regularly experience NSHEs (one third of this study 
population), or only experience them during the day-
time (two thirds of this study population), the real world 
burden in those that have regular hypoglycaemic events 
may be higher than previously reported. It is important 
to consider that the current results only relate to a four-
week period, so further research is warranted to better 
understand this issue.
In the present study, we investigated patients’ self-
reported ability to recognise the symptoms of hypo-
glycaemia. There is no consensus on how to classify 
awareness, however our method benefits from the use of 
three categories (instead of two—aware/unaware—as in 
the Clarke [31] and Gold [32] methods), which enables 
identification of the gradual loss of awareness. In addi-
tion, it is the only method proven to perform similarly 
across language barriers [33]. The proportion of respon-
dents in Austria reportedly ‘aware’ of hypoglycaemic 
symptoms was higher than the average across Northern 
and Central Europe in both T1DM (48 % versus 36 %) 
and T2DM respondents (43–61 % versus 36–51 %) [15]. 
Despite higher awareness levels in Austria compared to 
the rest of Northern and Central Europe, a substantial 
proportion of our study population (47 %) had impaired 
awareness or unawareness. Impaired awareness has been 
linked to reduced adherence to recommended changes 
in insulin regimen [34], and has been reported as the 
most important risk factor for severe hypoglycaemia [35]. 
T2DM in Austria. In addition, it provides insight into 
hypoglycaemic awareness, patient–physician commu-
nication and the health-related and economic impacts 
linked to non-severe events.
The frequency of NSHEs in T1DM respondents in Aus-
tria (1.6 per week), is slightly lower than in three previ-
ously conducted studies in Northern and Central Europe, 
which reported NSHE frequencies of 1.8, 2.0 and 2.2 per 
respondent, per week [15, 20, 21]. However, event rates 
in T2DM respondents (0.4 per week) are similar to those 
reported in a prospective single-centred study in Scot-
land (0.3 per week) [8]. The Austrian NSHE rate is gen-
erally similar to the mean rate previously reported for 
Europe (based on seven countries including Austria) 
[15, 16], across all patient groups (85 versus 91 in T1DM 
and 15–28 versus 20–35 in T2DM) [15, 16]. The propor-
tion of events which occur at night-time in Austria (19 % 
in T1DM and 15–22 % in T2DM) is also comparable to 
the results across all European countries studied (22 % in 
T1DM and 22–32 % in T2DM) [15].
In Austria, the self-reported NSHE rate in T1DM 
respondents is four times greater than the rates reported 
by T2DM respondents. It has previously been shown that 
the risk of hypoglycaemia in people with insulin-treated 
Table 6 Direct and indirect economic impacts of hypogly-
caemic events
Last NSHE across all respondents T1DM T2DM
NSHE resulting in contact with HCP
Overall, % (n) 3 (12) 10 (33)
Daytime NSHE, % (n) 3 (11) 10 (27)
Nocturnal NSHE, % (n) 1 (1) 9 (6)
Self-reported number of BGM tests use in the aver-
age week, mean
30.4 22.2
Mean increase in BGM use in the 7 days following a NSHE
Overall 4.1 3.7
Daytime NSHE 3.5 3.8
Nocturnal NSHE 5.9 3.1
Last NSHE from employed respondents
NSHE leading to lost work time, %
Overall, % (n) 8 (23) 14 (12)
Daytime NSHE, % (n) 8 (21) 13 (8)
Nocturnal NSHE, % (n) 4 (2) 18 (4)
Mean work time lost after a NSHE (in respondents who 
lost work time), mins
Overall 181.9 256.5
Daytime NSHE 185.0 131.3
Nocturnal NSHE 150.0 507.0
NSHE leading to self-reported inability to complete 
a work task in a timely manner, %
42 38
NSHE resulting in self-reported difficulty concen-
trating at work, %
27 28
BGM blood glucose measurement, HCP healthcare professional, Mins 
Minutes, N/A Not applicable, NSHE Non-severe hypoglycaemic event, SHE 
severe hypoglycaemic event, T1DM Type 1 diabetes mellitus, T2DM Type 2 
diabetes mellitus
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Given that T2DM is associated with fewer hypoglycaemic 
events, our study may underestimate the true frequency 
of events among respondents with T1DM.
Secondly, the survey relies on respondents ability to 
recall their NSHEs frequency over the preceding 7-day 
period, which might have introduced a bias related to the 
interpretation of symptoms. However, a previous study 
reported that a respondent’s recall of NSHEs during the 
previous week was not significantly different from the 
prospective recording of events over the same time period 
[14]. The recruitment method, which required having an 
email address and used online panels to locate patients, 
could have introduced selection bias. However, the inter-
net penetration rate in Austria is higher than the average 
across Europe, based on data from 2012 (80 % in Austria 
compared to 73 % across the European Union and 64 % 
across Europe) [40] and recruitment was done via broad 
panels reflective of the general population. As respon-
dents were not informed that the survey was about hypo-
glycaemia prior to enrolling, there is no reason to suggest 
any selection bias towards people struggling with hypo-
glycaemia in the first wave of the study. However since 
the response rates for waves of the study diminished (82, 
72 and 67 % of respondents completed wave two, three 
and four respectively), we cannot rule out the possibility 
that later waves were completed by respondents who had 
more experience of hypoglycaemic events.
Despite these limitations, this study provides impor-
tant real-world rates of hypoglycaemia in Austria, both 
during the day and at night-time, addressing the lack 
of data available for this population. Many patients are 
unable to recognise the symptoms of a hypoglycaemic 
event, and also express a reluctance to discuss their hypo-
glycaemia with physicians. The importance of improving 
glycaemic control is evidenced by the negative impact on 
healthcare resource use and work productivity in Austria 
that results from even non-severe events.
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A number of previous studies have shown a statistically 
significant (p < 0.05) increase in SHEs in patients with 
reduced awareness [34, 36–39]. In line with this, our study 
showed a trend (although not statistically significant) for 
increased SHE and NSHE rates with reduced levels of 
awareness (in respondents with T1DM). In the overall 
European study, these trends were statistically signifi-
cant (p < 0.05) [16]. This could be explained by unaware 
respondents not taking preventative action to stop the 
onset of hypoglycaemia, because they are unable to rec-
ognise the symptoms of low blood sugar. Additionally, 
this inability may cause respondents to overcompensate 
by testing their blood glucose more frequently, resulting 
in the identification of more events.
We also found that a high proportion of respondents 
in Austria were reluctant to discuss their hypoglycae-
mia with their GP/specialist (67 % of T1DM and 49 % 
of T2DM; comparable to the mean percentages across 
Northern and Central Europe) [15]. This may be due to 
wider factors such as a fear of losing driving privileges 
[11], impacts in the work environment, or concerns 
that their GP may think they have poor control of their 
diabetes.
Unsurprisingly, NSHE were associated with reduced 
physical and emotional well-being, regardless of the 
time of day the NSHE occurred. The negative emotional 
impact of NSHEs was comparable across diabetes types; 
tiredness/fatigue and reduced alertness were the most 
commonly reported effects in both T1DM and T2DM 
respondents. This supports a previous study in which 
patients reported that hypoglycaemia affects their daily 
life and causes anxiety [10]. The health-related impact 
of hypoglycaemia has been further confirmed using the 
EQ-5D and SF-36; a study of diabetes patients in the UK 
reported that as the frequency and severity of hypogly-
caemia increased, quality of life and health-related util-
ity decreased [7].
In our study, patients increased their self-monitoring 
of glucose levels in response to a NSHE. Whilst this is an 
appropriate adaptive behaviour which may help prevent 
new events in the short-term [11], it increases healthcare 
resource use (i.e. increase in BGM test-strip consump-
tion) and is therefore associated with a cost burden. 
This burden could be alleviated if NSHE frequency was 
reduced, through improved awareness and recognition 
of events. An additional contributor to the direct cost 
burden of NSHEs in Austria is patient contact with phy-
sicians to report their event. NSHE also present an indi-
rect cost burden in Austria through lost work time. This is 
reported in further detail by Geelhoed-Duijvestijn et al. 
[16].
Limitations of this study should be considered and 
have been discussed previously by Östenson et al. [15] 
and Geelhoed-Duijvestijn et al. [16]. Respondent demo-
graphics show that 6 % of Austrian respondents with 
T1DM were receiving basal-only insulin, however this 
formulation should only be used in patients with T2DM, 
and therefore we presume that most of these respon-
dents incorrectly reported their diabetes type as T1DM. 
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